SEC Form 4 · accession 0000911916-17-000026
CoLucid Pharmaceuticals, Inc. · CLCD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew D Dallas
Officer — Chief Financial Officer
Period of report
Jan 3, 2017
Accepted (ET)
Jan 4, 2017 · 4:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348649
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 3, 2017 | S | 1,473 | $36.25 | D | 40,128 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Securities sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Dallas on August 15, 2016. One purpose of the plan is to sell shares of common stock acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan.